What Do We Do?
Mass spectrometers and other related analytical techniques have continued to improve at a rapid pace over the past few decades. At Bioinformatics Solutions Inc. (BSI), we understand how important it is for researchers to have software that is up to date and can handle the continuously improving data outputs.
Founded in March 2000 in Waterloo, Ontario, Canada, BSI is best known in the proteomics research community for the development of the software; PEAKS. PEAKS is used to identify and quantify proteins in very complex biological samples with LC-MS. At BSI, our group is continually involved in research and the advancement of our algorithms to provide solutions to facilitate the understanding of life sciences and are designed to elucidate important biological questions. As an instrument vendor neutral company, BSI works directly with each vendor to ensure accurate results and to maximize the information extracted from the raw mass spectrometry data. In addition, we closely collaborate with our users and experts worldwide.
This allows us to simultaneously help them with their research and their input helps shape future PEAKS products to continue to improve the solution that can be provided. See BSI Publications for more information on algorithms underlying our software and applications.
For over 20 years Bioinformatics Solutions Inc (BSI) has been one of the major driving forces for mass spectrometry data analysis. BSI is an AI-driven biotechnology company that is committed to advancing research by providing innovative proteomics solutions with machine learning and ground-breaking algorithms integrated into the latest mass spectrometry technology. Our mission is to facilitate drug discovery and advance the frontier of biological research through AI-driven commercial software and professional services.
At BSI, we collaborate with leading researchers from the academic, pharmaceutical, and biotechnology sectors, with the aim to provide advanced AI-based solutions to gain comprehensive knowledge in proteomics, immunopeptidomics, and biomedicine research. We believe our strongest asset is our ability to bring the right people together: pioneering scientists, award-winning researchers, technology developers, and AI innovators to execute our mission.